iopamidol
Generic: IOPAMIDOL·Brand: IOPAMIDOL, IOPAMIDOL-200, IOPAMIDOL-200 IN PLASTIC CONTAINER, IOPAMIDOL-250, IOPAMIDOL-250 IN PLASTIC CONTAINER, IOPAMIDOL-300, IOPAMIDOL-300 IN PLASTIC CONTAINER, IOPAMIDOL-370, IOPAMIDOL-370 IN PLASTIC CONTAINER, ISOVUE-128, ISOVUE-200, ISOVUE-250, ISOVUE-300, ISOVUE-370, ISOVUE-M 200, ISOVUE-M 300, SCANLUX-300, SCANLUX-370
iopamidol: 1 clinical trial tracked.
iopamidol evidence translation
What we can confirm
1 tracked trial
No verified listed developer
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about iopamidol, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trials (1)
A Phase 1B Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer
Primary endpoint: Number of Dose-limiting Toxicities (DLTs)
Interventionalopen4 targetStarted 2020-10Completion 2021-101 site · United StatesJennifer Lee Caswell-Jin